Galecteye Pharma ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2016
N/A
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 31.2% 27.4% 28.2% 25.9%  
Credit score (0-100)  0 1 3 3 3  
Credit rating  N/A C B B B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2016
N/A
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Net sales  0 0 0 0 0  
Gross profit  0.0 -17.1 -10.0 -5.0 -6.3  
EBITDA  0.0 -17.1 -10.0 -5.0 -6.3  
EBIT  0.0 -17.1 -10.0 -5.0 -6.3  
Pre-tax profit (PTP)  0.0 -18.2 -11.1 -6.0 -7.3  
Net earnings  0.0 -18.2 -11.1 -6.0 -7.3  
Pre-tax profit without non-rec. items  0.0 -18.2 -11.1 -6.0 -7.3  

 
See the entire income statement

Balance sheet (kDKK) 
2016
N/A
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 31.8 20.8 14.8 7.5  
Interest-bearing liabilities  0.0 101 102 103 104  
Balance sheet total (assets)  0.0 142 130 124 118  

Net Debt  0.0 -41.2 -28.3 -21.0 -13.7  
 
See the entire balance sheet

Volume 
2016
N/A
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 -17.1 -10.0 -5.0 -6.3  
Gross profit growth  0.0% 0.0% 41.3% 50.2% -25.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 142 130 124 118  
Balance sheet change%  0.0% 0.0% -8.4% -4.8% -5.0%  
Added value  0.0 -17.1 -10.0 -5.0 -6.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2016
N/A
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% -12.0% -7.4% -3.9% -5.2%  
ROI %  0.0% -12.9% -7.9% -4.2% -5.4%  
ROE %  0.0% -57.0% -42.0% -33.8% -65.4%  

Solidity 
2016
N/A
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Equity ratio %  0.0% 22.4% 16.0% 11.9% 6.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 241.0% 281.8% 420.5% 220.0%  
Gearing %  0.0% 317.3% 490.7% 697.5% 1,388.6%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 2.1% 1.0% 1.0% 1.0%  

Liquidity 
2016
N/A
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Quick Ratio  0.0 15.2 17.4 19.9 18.9  
Current Ratio  0.0 15.2 17.4 19.9 18.9  
Cash and cash equivalent  0.0 142.3 130.3 124.1 117.8  

Capital use efficiency 
2016
N/A
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 132.9 122.8 117.8 111.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2016
N/A
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0